TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06783309: CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

Sponsor: COUR Pharmaceutical Development Company, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 72 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,172,940

Rescue Site Savings

+$1,439,220

Unlock Full NCT06783309 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06783309 Rescue Dossier →